These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 33812834)

  • 1. Outcomes of Direct Oral Anticoagulants in Atrial Fibrillation Patients Across Different Body Mass Index Categories.
    Barakat AF; Jain S; Masri A; Alkukhun L; Senussi M; Sezer A; Wang Y; Thoma F; Bhonsale A; Saba S; Mulukutla S
    JACC Clin Electrophysiol; 2021 May; 7(5):649-658. PubMed ID: 33812834
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the efficacy of direct oral anticoagulants (DOACs) in comparison to warfarin in morbidly obese patients.
    Kalani C; Awudi E; Alexander T; Udeani G; Surani S
    Hosp Pract (1995); 2019 Oct; 47(4):181-185. PubMed ID: 31580732
    [No Abstract]   [Full Text] [Related]  

  • 3. Comparing the Efficacy and Safety of Direct Oral Anticoagulants With Warfarin in the Morbidly Obese Population With Atrial Fibrillation.
    Kido K; Ngorsuraches S
    Ann Pharmacother; 2019 Feb; 53(2):165-170. PubMed ID: 30130979
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of Direct Oral Anticoagulants for Atrial Fibrillation Across Body Mass Index Categories.
    Kaplan RM; Tanaka Y; Passman RS; Fine M; Rasmussen-Torvik LJ; Vupputuri S; Martin K; Khan SS
    J Am Heart Assoc; 2020 Dec; 9(24):e017383. PubMed ID: 33302751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of Direct Oral Anticoagulants Versus Warfarin in Patients with Atrial Fibrillation Across BMI Categories: A Systematic Review and Meta-Analysis.
    Zhou Y; Ma J; Zhu W
    Am J Cardiovasc Drugs; 2020 Feb; 20(1):51-60. PubMed ID: 31342343
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prescription Patterns and Outcomes of Patients With Atrial Fibrillation Treated With Direct Oral Anticoagulants and Warfarin: A Real-World Analysis.
    Kattoor AJ; Pothineni NV; Goel A; Syed M; Syed S; Paydak H; Mehta JL
    J Cardiovasc Pharmacol Ther; 2019 Sep; 24(5):428-434. PubMed ID: 31035795
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of direct oral factor Xa inhibitors compared with warfarin in patients with morbid obesity: a single-centre, retrospective analysis of chart data.
    Kushnir M; Choi Y; Eisenberg R; Rao D; Tolu S; Gao J; Mowrey W; Billett HH
    Lancet Haematol; 2019 Jul; 6(7):e359-e365. PubMed ID: 31133411
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A single center retrospective cohort study evaluating use of direct oral anticoagulants (DOACs) in morbidly obese veteran population.
    Patil T; Lebrecht M
    Thromb Res; 2020 Aug; 192():124-130. PubMed ID: 32473496
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Periprocedural Outcomes of Direct Oral Anticoagulants Versus Warfarin in Nonvalvular Atrial Fibrillation.
    Nazha B; Pandya B; Cohen J; Zhang M; Lopes RD; Garcia DA; Sherwood MW; Spyropoulos AC
    Circulation; 2018 Oct; 138(14):1402-1411. PubMed ID: 29794081
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Body Mass Index and Clinical Outcomes in Asian Patients With Atrial Fibrillation Receiving Oral Anticoagulation.
    Lee SR; Choi EK; Jung JH; Park SH; Han KD; Oh S; Lip GYH
    Stroke; 2021 Jan; 52(2):521-530. PubMed ID: 33423512
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of Direct Oral Anticoagulation Management Strategies With Clinical Outcomes for Adults With Atrial Fibrillation.
    Derington CG; Goodrich GK; Xu S; Clark NP; Reynolds K; An J; Witt DM; Smith DH; O'Keeffe-Rosetti M; Lang DT; Ho PM; Cheetham TC; Comer AC; King JB
    JAMA Netw Open; 2023 Jul; 6(7):e2321971. PubMed ID: 37410461
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative effectiveness and safety of direct oral anticoagulants versus vitamin K antagonists in nonvalvular atrial fibrillation: a Canadian multicentre observational cohort study.
    Durand M; Schnitzer ME; Pang M; Carney G; Eltonsy S; Filion KB; Fisher A; Jun M; Kuo IF; Renoux C; Paterson JM; Quail J; Matteau A;
    CMAJ Open; 2020; 8(4):E877-E886. PubMed ID: 33355273
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Direct Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation and Low Body Weight.
    Lee SR; Choi EK; Park CS; Han KD; Jung JH; Oh S; Lip GYH
    J Am Coll Cardiol; 2019 Mar; 73(8):919-931. PubMed ID: 30819360
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risks and benefits of oral anticoagulants for stroke prophylaxis in atrial fibrillation according to body mass index: Nationwide cohort study of primary care records in England.
    Nakao YM; Nakao K; Wu J; Nadarajah R; Camm AJ; Gale CP
    EClinicalMedicine; 2022 Dec; 54():101709. PubMed ID: 36353266
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative effectiveness, safety, and costs of rivaroxaban and warfarin among morbidly obese patients with atrial fibrillation.
    Peterson ED; Ashton V; Chen YW; Wu B; Spyropoulos AC
    Am Heart J; 2019 Jun; 212():113-119. PubMed ID: 30981035
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The HAS-BLED score has better prediction accuracy for major bleeding than CHADS2 or CHA2DS2-VASc scores in anticoagulated patients with atrial fibrillation.
    Roldán V; Marín F; Manzano-Fernández S; Gallego P; Vílchez JA; Valdés M; Vicente V; Lip GY
    J Am Coll Cardiol; 2013 Dec; 62(23):2199-204. PubMed ID: 24055744
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rivaroxaban Versus Warfarin for Stroke Prevention and Venous Thromboembolism Treatment in Extreme Obesity and High Body Weight.
    Perales IJ; San Agustin K; DeAngelo J; Campbell AM
    Ann Pharmacother; 2020 Apr; 54(4):344-350. PubMed ID: 31672028
    [No Abstract]   [Full Text] [Related]  

  • 18. Association of Ischemic Stroke, Major Bleeding, and Other Adverse Events With Warfarin Use vs Non-vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation With a History of Intracranial Hemorrhage.
    Tsai CT; Liao JN; Chiang CE; Lin YJ; Chang SL; Lo LW; Hu YF; Tuan TC; Chung FP; Chao TF; Lip GYH; Chen SA
    JAMA Netw Open; 2020 Jun; 3(6):e206424. PubMed ID: 32478848
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-Term Population-Based Cerebral Ischemic Event and Cognitive Outcomes of Direct Oral Anticoagulants Compared With Warfarin Among Long-term Anticoagulated Patients for Atrial Fibrillation.
    Jacobs V; May HT; Bair TL; Crandall BG; Cutler MJ; Day JD; Mallender C; Osborn JS; Stevens SM; Weiss JP; Woller SC; Bunch TJ
    Am J Cardiol; 2016 Jul; 118(2):210-4. PubMed ID: 27236255
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Outcomes in Patients With Atrial Fibrillation Treated With Non-Vitamin K Oral Anticoagulants Across Varying Body Mass Index.
    Fritz Hansson A; Jensevik Eriksson K; Christersson C; Held C; Batra G
    J Am Heart Assoc; 2023 Nov; 12(22):e030829. PubMed ID: 37947112
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.